抗骨橋素抗體(Anti-OPN)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Anti-Osteopontin Antibody (Anti-OPN)
SPP1; BNSP; BSPI; ETA1; Secreted Phosphoprotein 1; Bone Sialoprotein I; Early T-Lymphocyte Activation 1; Nephropontin; Urinary stone protein; Uropontin
- 編號(hào)UAEA899Hu
- 物種Homo sapiens (Human，人) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法間接法
- 反應(yīng)時(shí)長(zhǎng)2h, 30min
- 檢測(cè)范圍3.12-200ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于1.22ng/mL.
- 樣本類(lèi)型serum, plasma and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1785 ¥ 2550 ¥ 11475 ¥ 21675 ¥ 178500
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)抗骨橋素抗體(Anti-OPN)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的抗骨橋素抗體(Anti-OPN)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 90-101 | 96 |
| EDTA plasma(n=5) | 82-98 | 94 |
| heparin plasma(n=5) | 97-104 | 101 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的抗骨橋素抗體(Anti-OPN)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中抗骨橋素抗體(Anti-OPN)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 92-101% | 80-101% | 97-105% | 91-99% |
| EDTA plasma(n=5) | 80-98% | 99-105% | 79-98% | 80-101% |
| heparin plasma(n=5) | 99-105% | 93-105% | 96-105% | 93-101% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100μL，37°C孵育1小時(shí)；
4. 洗板5次；
5. 加TMB底物90µL，37°C孵育10-20分鐘；
6. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將抗原包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的抗骨橋素抗體(Anti-OPN)與連接于固相載體上的抗原結(jié)合，然后加入HRP標(biāo)記的二抗，徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的抗骨橋素抗體(Anti-OPN)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UEPA899Hu61 | 骨橋素(OPN)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPA899Hu63 | 骨橋素(OPN)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA899Hu02 | 骨橋素(OPN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPA899Hu62 | 骨橋素(OPN)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA899Hu61 | 骨橋素(OPN)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAA899Hu06 | 骨橋素(OPN)多克隆抗體 | Testing in progress |
| UPAA899Hu02 | 骨橋素(OPN)多克隆抗體 | WB; IHC; FCM |
| ULAA899Hu71 | 骨橋素(OPN)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAA899Hu22 | 骨橋素(OPN)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA899Hu23 | 骨橋素(OPN)單克隆抗體 | WB |
| UMAA899Hu24 | 骨橋素(OPN)單克隆抗體 | WB |
| UMAA899Hu25 | 骨橋素(OPN)單克隆抗體 | WB |
| UMAA899Hu21 | 骨橋素(OPN)單克隆抗體 | WB |
| USEA899Hu | 骨橋素(OPN)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UAEA899Hu | 抗骨橋素抗體(Anti-OPN)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| USCA899Hu | 骨橋素(OPN)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA899Hu | 骨橋素(OPN)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA899Hu01 | 骨橋素(OPN)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of Biomedical Materials Research Part A | Proliferation and osteogenesis of immortalized bone marrow-derived mesenchymal stem cells in porous polylactic glycolic acid scaffolds under perfusion culture [PubMed: 19280635] |
| Osteoarthritis and Cartilage | Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients [PubMed: 19747583] |
| The Journal of Rheumatology | Thrombin-cleaved osteopontin levels in synovial fluid correlate with disease severity of knee osteoarthritis. [Jrheum: source] |
| International Journal of Pharmaceutics | Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly(amino ester) [ScienceDirect: S0378517312003742] |
| European Cells and matreials | The use of non-viral gene vectors for bioactive poly-(D, L-lactide) implant surfaces in bone tissue engineering [Ecmjournal: Source] |
| Journal of Equine Veterinary Science | Influence of Seminal Plasma Antioxidants and Osteopontin on Fertility of the Arabian Horse [ScienceDirect: Source] |
| Basic & Clinical Pharmacology & Toxicology | Treatment with Carnitine Enhances Bone Fracture Healing under Osteoporotic and/or Inflammatory Conditions [Wiley:Source] |
| Journal of Cellular Biochemistry | Tension Force-Induced ATP Promotes Osteogenesis Through P2X7 Receptor in Osteoblasts [Pubmed:24905552] |
| Naunyn-Schmiedeberg's Archives of Pharmacology | Treatment with α-lipoic acid enhances the bone healing after femoral fracture model of rats [Pubmed:25038619] |
| J Endocrinol Invest.? | The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders [Pubmed:25245337] |
| FEBS Letters | Low-intensity pulsed ultrasound-induced ATP increases bone formation via the P2X7 receptor in osteoblast-like MC3T3-E1 cells [Pubmed:25542352] |
| Gene | Effects of magnesium degradation products on mesenchymal stem cell fate and osteoblastogenesis [PubMed: 26283150] |
| Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer [PubMed: 26266370] |
| Journal of Biomaterials and Tissue Engineering | Osteogenic Differentiation of Canine Adipose Stem Cells Cultured in Alginate-Fibrin-Based Hydrogel [Content: Asp] |
| Primasari | Osteopontin level correlates negatively with tumor shrinkage in neoadjuvant chemoradiation of locally advanced rectal cancer [Index.Php: Amor] |
| Int J Biol Sci | Defective Initiation of Liver Regeneration in Osteopontin-Deficient Mice after Partial Hepatectomy due to Insufficient Activation of IL-6/Stat3 Pathway [PubMed: 26327817] |
| Journal of Kunming Medical University / Kunming Yike Daxue Xuebao | Perioperative Clinical Investigation of Serum VEGF, CA19-9 and OPN Levels in Patients with Colorectal Carcinoma. [Ebscohost] |
| Am J Pathol.? | Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy. [Pubmed:26963343] |
| circulation journal | Stenotic Bicuspid and Tricuspid Aortic Valves - Micro-Computed Tomography and Biological Indices of Calcification. [pubmed:28344201] |
| Journal of Cardiovascular Electrophysiology | Effect of Cardiac Resynchronization Therapy on Myocardial Fibrosis and Relevant Cytokines in a Canine Model With Experimental Heart Failure. [pubmed:28127817] |
| American Journal of Translational Research | Osteopontin stimulates matrix metalloproteinase expression through the nuclear factor-κB signaling pathway in rat temporomandibular joint and condylar chondrocytes. [pubmed:28337262] |
| Diabetes Care | Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans [pubmed:29212824] |
| Biomedicine & pharmacotherapy | Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation. [pubmed:28742995] |
| Journal of?Alzheimers?Disease | Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods [Pubmed:30040720] |
| Indian?Journal?of?Nephrology | Osteopontin, cardiovascular risk factors and carotid intima-Media thickness in chronic kidney disease [id:233806] |
| Carbon | In Situ Self-Assembly of Graphene Oxide/Polydopamine/Sr2+ Nanosheets on Titanium Surfaces for Enhanced Osteogenic Differentiation of Mesenchymal Stem Cells [Doi: 10.1016/j.carbon.2018.10.081] |
| current?eye?research | Detection of proteins associated with extracellular matrix regulation in the aqueous humour of patients with primary glaucoma. [Pubmed: 30994369] |
| Journal of Proteomics | Identification of urinary candidate biomarkers of cisplatin-induced nephrotoxicity in patients with carcinoma [Pubmed: 31629959] |
| Acta Biomaterialia | Inflammatory response to magnesium-based biodegradable implant materials [Pubmed: 31610341] |
| Journal of Clinical Medicine | Calcium Kidney Stones are Associated with Increased Risk of Carotid Atherosclerosis: the Link between Urinary Stone Risks, Carotid Intima-Media Thickness, and … [Pubmed: 32182704] |
| EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | Febuxostat attenuates vascular calcification induced by vitamin D3 plus nicotine in rats [Pubmed: 33010420] |
| [ENGINEERING OF BIOMATERIALS | Osteoconductive potential of PLGA/bioglass composite biomaterials [] |
| Biomolecules | Structural Constraint of Osteopontin Facilitates Efficient Binding to CD44 [34070790] |
| Structural Changes and Detection of Liver Fibrosis¨CRelated Protein Levels in Coculture of Alveolar Echinococcosis-Protoscoleces and Human Hepatic Stellate cells [] | |
| Parasit Vectors | Structural changes and expression of hepatic fibrosis-related proteins in coculture of Echinococcus multilocularis protoscoleces and human hepatic stellate?… [34857049] |
| Medicina (Kaunas) | Plasma Concentrations of New Biochemical Markers of Atherosclerosis in Patients with Dyslipidemia—A Pilot Study [Pubmed:35743980] |
留言咨詢(xún)
